ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-17P2271
Home | Market Reports | Health| Pharmacy
Global Radiopharmaceuticals in Nuclear Medicine Market Insights Forecast to 2028
BUY CHAPTERS

Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2025

Code: QYRE-Auto-17P2271
Report
January 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bracco Imaging
Company
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
Siemens AG
Lantheus
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng

Radiopharmaceuticals in Nuclear Medicine Market Size

The global market for Radiopharmaceuticals in Nuclear Medicine was valued at US$ 6124 million in the year 2024 and is projected to reach a revised size of US$ 10180 million by 2031, growing at a CAGR of 7.3% during the forecast period.

Radiopharmaceuticals in Nuclear Medicine Market

Radiopharmaceuticals in Nuclear Medicine Market

Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.
Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.
There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.
Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.
Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals in Nuclear Medicine.
The Radiopharmaceuticals in Nuclear Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radiopharmaceuticals in Nuclear Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceuticals in Nuclear Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Radiopharmaceuticals in Nuclear Medicine Market Report

Report Metric Details
Report Name Radiopharmaceuticals in Nuclear Medicine Market
Accounted market size in year US$ 6124 million
Forecasted market size in 2031 US$ 10180 million
CAGR 7.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Dongcheng
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Radiopharmaceuticals in Nuclear Medicine Market growing?

Ans: The Radiopharmaceuticals in Nuclear Medicine Market witnessing a CAGR of 7.3% during the forecast period 2025-2031.

What is the Radiopharmaceuticals in Nuclear Medicine Market size in 2031?

Ans: The Radiopharmaceuticals in Nuclear Medicine Market size in 2031 will be US$ 10180 million.

Who are the main players in the Radiopharmaceuticals in Nuclear Medicine Market report?

Ans: The main players in the Radiopharmaceuticals in Nuclear Medicine Market are Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Dongcheng

What are the Application segmentation covered in the Radiopharmaceuticals in Nuclear Medicine Market report?

Ans: The Applications covered in the Radiopharmaceuticals in Nuclear Medicine Market report are Oncology, Cardiology, Other

What are the Type segmentation covered in the Radiopharmaceuticals in Nuclear Medicine Market report?

Ans: The Types covered in the Radiopharmaceuticals in Nuclear Medicine Market report are Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals

Recommended Reports

Radiopharmaceutical Market

Nuclear Medicine Imaging

Therapeutic Applications

1 Radiopharmaceuticals in Nuclear Medicine Market Overview
1.1 Product Definition
1.2 Radiopharmaceuticals in Nuclear Medicine by Type
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapy Radiopharmaceuticals
1.3 Radiopharmaceuticals in Nuclear Medicine by Application
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Value by Application (2024 VS 2031)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Global Radiopharmaceuticals in Nuclear Medicine Market Size Estimates and Forecasts
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue 2020-2031
1.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales 2020-2031
1.4.3 Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Radiopharmaceuticals in Nuclear Medicine Market Competition by Manufacturers
2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Radiopharmaceuticals in Nuclear Medicine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Type & Application
2.7 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Date of Enter into This Industry
2.8 Global Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
2.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
2.8.3 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Radiopharmaceuticals in Nuclear Medicine Market Scenario by Region
3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2020-2031
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2020-2025
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2026-2031
3.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2020-2031
3.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2020-2025
3.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2026-2031
3.4 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.4.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
3.4.3 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
3.5.3 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Region
3.6.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2031)
3.6.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.7.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
3.7.3 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2025)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2026-2031)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2020-2031)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2025)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2026-2031)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2020-2031)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2025)
5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2026-2031)
5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2020-2031)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2025)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2026-2031)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2020-2031)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Cardinal Health
6.1.1 Cardinal Health Company Information
6.1.2 Cardinal Health Description and Business Overview
6.1.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.1.5 Cardinal Health Recent Developments/Updates
6.2 GE Healthcare
6.2.1 GE Healthcare Company Information
6.2.2 GE Healthcare Description and Business Overview
6.2.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.2.5 GE Healthcare Recent Developments/Updates
6.3 Jubilant Pharma
6.3.1 Jubilant Pharma Company Information
6.3.2 Jubilant Pharma Description and Business Overview
6.3.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.3.5 Jubilant Pharma Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Curium Pharma
6.5.1 Curium Pharma Company Information
6.5.2 Curium Pharma Description and Business Overview
6.5.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.5.5 Curium Pharma Recent Developments/Updates
6.6 SIEMENS
6.6.1 SIEMENS Company Information
6.6.2 SIEMENS Description and Business Overview
6.6.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.6.5 SIEMENS Recent Developments/Updates
6.7 Lantheus
6.7.1 Lantheus Company Information
6.7.2 Lantheus Description and Business Overview
6.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.7.5 Lantheus Recent Developments/Updates
6.8 Bracco Imaging
6.8.1 Bracco Imaging Company Information
6.8.2 Bracco Imaging Description and Business Overview
6.8.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.8.5 Bracco Imaging Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Company Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 Aurobindo Pharma
6.11.1 Aurobindo Pharma Company Information
6.11.2 Aurobindo Pharma Description and Business Overview
6.11.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.11.5 Aurobindo Pharma Recent Developments/Updates
6.12 Mundipharma
6.12.1 Mundipharma Company Information
6.12.2 Mundipharma Description and Business Overview
6.12.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.12.5 Mundipharma Recent Developments/Updates
6.13 China Isotope & Radiation
6.13.1 China Isotope & Radiation Company Information
6.13.2 China Isotope & Radiation Description and Business Overview
6.13.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.13.5 China Isotope & Radiation Recent Developments/Updates
6.14 Dongcheng
6.14.1 Dongcheng Company Information
6.14.2 Dongcheng Description and Business Overview
6.14.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.14.5 Dongcheng Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
7.2 Radiopharmaceuticals in Nuclear Medicine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process Analysis
7.4 Radiopharmaceuticals in Nuclear Medicine Sales and Marketing
7.4.1 Radiopharmaceuticals in Nuclear Medicine Sales Channels
7.4.2 Radiopharmaceuticals in Nuclear Medicine Distributors
7.5 Radiopharmaceuticals in Nuclear Medicine Customer Analysis
8 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
8.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
8.2 Radiopharmaceuticals in Nuclear Medicine Market Drivers
8.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
8.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bracco Imaging
Company
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
Siemens AG
Lantheus
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng
List of Tables
 Table 1. Global Radiopharmaceuticals in Nuclear Medicine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Radiopharmaceuticals in Nuclear Medicine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Radiopharmaceuticals in Nuclear Medicine Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Radiopharmaceuticals in Nuclear Medicine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Type & Application
 Table 12. Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Radiopharmaceuticals in Nuclear Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2020-2025)
 Table 19. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2026-2031)
 Table 21. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2020-2025)
 Table 23. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2026-2031)
 Table 25. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Radiopharmaceuticals in Nuclear Medicine Sales (K Dose) by Type (2020-2025)
 Table 51. Global Radiopharmaceuticals in Nuclear Medicine Sales (K Dose) by Type (2026-2031)
 Table 52. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2020-2025)
 Table 53. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2026-2031)
 Table 54. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2020-2025)
 Table 57. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2026-2031)
 Table 58. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Radiopharmaceuticals in Nuclear Medicine Sales (K Dose) by Application (2020-2025)
 Table 61. Global Radiopharmaceuticals in Nuclear Medicine Sales (K Dose) by Application (2026-2031)
 Table 62. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2020-2025)
 Table 63. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2026-2031)
 Table 64. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2020-2025)
 Table 67. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2026-2031)
 Table 68. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Dose) by Application (2026-2031)
 Table 70. Cardinal Health Company Information
 Table 71. Cardinal Health Description and Business Overview
 Table 72. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product
 Table 74. Cardinal Health Recent Developments/Updates
 Table 75. GE Healthcare Company Information
 Table 76. GE Healthcare Description and Business Overview
 Table 77. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product
 Table 79. GE Healthcare Recent Developments/Updates
 Table 80. Jubilant Pharma Company Information
 Table 81. Jubilant Pharma Description and Business Overview
 Table 82. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product
 Table 84. Jubilant Pharma Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. Novartis Radiopharmaceuticals in Nuclear Medicine Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Curium Pharma Company Information
 Table 91. Curium Pharma Description and Business Overview
 Table 92. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product
 Table 94. Curium Pharma Recent Developments/Updates
 Table 95. SIEMENS Company Information
 Table 96. SIEMENS Description and Business Overview
 Table 97. SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. SIEMENS Radiopharmaceuticals in Nuclear Medicine Product
 Table 99. SIEMENS Recent Developments/Updates
 Table 100. Lantheus Company Information
 Table 101. Lantheus Description and Business Overview
 Table 102. Lantheus Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Lantheus Radiopharmaceuticals in Nuclear Medicine Product
 Table 104. Lantheus Recent Developments/Updates
 Table 105. Bracco Imaging Company Information
 Table 106. Bracco Imaging Description and Business Overview
 Table 107. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product
 Table 109. Bracco Imaging Recent Developments/Updates
 Table 110. Bayer Company Information
 Table 111. Bayer Description and Business Overview
 Table 112. Bayer Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 113. Bayer Radiopharmaceuticals in Nuclear Medicine Product
 Table 114. Bayer Recent Developments/Updates
 Table 115. Eli Lilly Company Information
 Table 116. Eli Lilly Description and Business Overview
 Table 117. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 118. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product
 Table 119. Eli Lilly Recent Developments/Updates
 Table 120. Aurobindo Pharma Company Information
 Table 121. Aurobindo Pharma Description and Business Overview
 Table 122. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 123. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product
 Table 124. Aurobindo Pharma Recent Developments/Updates
 Table 125. Mundipharma Company Information
 Table 126. Mundipharma Description and Business Overview
 Table 127. Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 128. Mundipharma Radiopharmaceuticals in Nuclear Medicine Product
 Table 129. Mundipharma Recent Developments/Updates
 Table 130. China Isotope & Radiation Company Information
 Table 131. China Isotope & Radiation Description and Business Overview
 Table 132. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 133. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product
 Table 134. China Isotope & Radiation Recent Developments/Updates
 Table 135. Dongcheng Company Information
 Table 136. Dongcheng Description and Business Overview
 Table 137. Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 138. Dongcheng Radiopharmaceuticals in Nuclear Medicine Product
 Table 139. Dongcheng Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Radiopharmaceuticals in Nuclear Medicine Distributors List
 Table 143. Radiopharmaceuticals in Nuclear Medicine Customers List
 Table 144. Radiopharmaceuticals in Nuclear Medicine Market Trends
 Table 145. Radiopharmaceuticals in Nuclear Medicine Market Drivers
 Table 146. Radiopharmaceuticals in Nuclear Medicine Market Challenges
 Table 147. Radiopharmaceuticals in Nuclear Medicine Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Radiopharmaceuticals in Nuclear Medicine
 Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Type: 2024 & 2031
 Figure 4. Diagnostic Radiopharmaceuticals Product Picture
 Figure 5. Therapy Radiopharmaceuticals Product Picture
 Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application: 2024 & 2031
 Figure 8. Oncology
 Figure 9. Cardiology
 Figure 10. Other
 Figure 11. Global Radiopharmaceuticals in Nuclear Medicine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Radiopharmaceuticals in Nuclear Medicine Sales (2020-2031) & (K Dose)
 Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Average Price (US$/Dose) & (2020-2031)
 Figure 15. Radiopharmaceuticals in Nuclear Medicine Report Years Considered
 Figure 16. Radiopharmaceuticals in Nuclear Medicine Sales Share by Manufacturers in 2024
 Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Radiopharmaceuticals in Nuclear Medicine Players: Market Share by Revenue in Radiopharmaceuticals in Nuclear Medicine in 2024
 Figure 19. Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2020-2031)
 Figure 22. North America Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2020-2031)
 Figure 26. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2020-2031)
 Figure 34. China Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. U.A.E Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Radiopharmaceuticals in Nuclear Medicine by Type (2020-2031)
 Figure 56. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Dose) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Radiopharmaceuticals in Nuclear Medicine by Application (2020-2031)
 Figure 59. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Dose) by Application (2020-2031)
 Figure 60. Radiopharmaceuticals in Nuclear Medicine Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Radiopharmaceutical Therapy Market Research Report 2025
Global Nuclear Medicine Radiopharmaceuticals Market Research Report 2024
Global Diagnostic Nuclear Medicines Market Insights Forecast to 2030
Global Diagnostic Radioisotopes Market Insights Forecast to 2030
Global SPECT and PET Radiopharmaceuticals Market Research Report 2024
Global Diagnostic Radiopharmaceuticals Market Research Report 2024
Global Radiopharmaceutical Market Research Report 2025
Global Nuclear Medicine Market Research Report 2025
Global Targeted Radiopharmaceuticals Market Research Report 2024
Global Radiopharmaceuticals for Diagnosis Market Research Report 2024
Diagnostic Nuclear Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radioactive Therapeutic Drugs Market Research Report 2024
Global Therapeutic Radiopharmaceuticals Market Insights Forecast to 2030
Radiopharmaceutical Theranostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global SPECT Radiopharmaceuticals Market Research Report 2025
Global PET Radioisotope Radiopharmaceuticals in PET Imaging Market Research Report 2024
Global Radiopharmaceutical for Nuclear Medicine Market Research Report 2024
Global Radioisotopes in Medicine Market Research Report 2025
Global Therapeutic Radioisotopes Market Insights Forecast to 2030
Nuclear Medicine Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Multi-use Capsule-based Dry Powder Inhaler Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O16568
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Jet Lag Medicine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0R20253
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Ruxolitinib Phosphate Tablets Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3G16891
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global NaSSAs Antidepressants Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4B16895
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions